S. Ignatius Ou

PP01.08: Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa J. Cooper, Stephen V. Liu, Oliver Gautschi et autres

us, ch, kr, hk, sg, au, at, ca (code pays fourni par la source)

Table S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa Jamie Cooper, Stephen V. Liu, Oliver Pascal Gautschi et autres

Acquired genomic alterations identified by post-progression biopsies after selective RET inhibitors

Table S1 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa Jamie Cooper, Stephen V. Liu, Oliver Pascal Gautschi et autres

Clinical and Molecular Characteristics of Cases of RET Gain Identified by Next-Generation Sequencing after Selective RET Inhibitors

Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa Jamie Cooper, Stephen V. Liu, Oliver Pascal Gautschi et autres

Pre- and post-SRI next-generation sequencing results provided

Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa Jamie Cooper, Stephen V. Liu, Oliver Pascal Gautschi et autres

Clinical and Molecular Characteristics of Cases of Acquired MET Amplification Identified by Next-Generation Sequencing after Selective RET Inhibitors

Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa Jamie Cooper, Stephen V. Liu, Oliver Pascal Gautschi et autres

AbstractPurpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” …

The “Inflammatory-Mutagenic” Landscape of Systemic Sclerosis (SSc)-Associated Lung Cancer: Distinct Genomics and Therapeutic Implications

N. Triphuridet, S. Ignatius Ou

th (code pays fourni par la source)

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium

Sarah Waliany, Alissa Jamie Cooper, Stephen V. Liu, Oliver Gautschi et autres

PURPOSE: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. EXPERIMENTAL DESIGN: We established "RETgistry," …

us, ch, kr, hk, sg, au, at, ca (code pays fourni par la source)